Focus Partners Wealth
CORT icon

Focus Partners Wealth’s Corcept Therapeutics CORT Stock Holding History

Focus Partners Wealth’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.32M Sell
32,739
-12,539
-28% -$469K ﹤0.01% 1491
2025
Q4 		$1.58M Buy
45,278
+455
+1% +$35.7K ﹤0.01% 1433
2025
Q3 		$3.73M Buy
44,823
+11,317
+34% +$819K 0.01% 837
2025
Q2 		$2.46M Buy
33,506
+263
+0.8% +$19.1K 0.01% 852
2025
Q1 		$3.8M Buy
33,243
+170
+0.5% +$10.3K 0.01% 703
2024
Q4 		$1.67M Buy
33,073
+675
+2% +$35.4K ﹤0.01% 893
2024
Q3 		$1.5M Buy
+32,398
New +$1.15M ﹤0.01% 840

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Focus Partners Wealth's CORT Position: Q1 2026 in Review

Focus Partners Wealth reduced its Corcept Therapeutics (CORT) stake by 28% in Q1 2026, selling an estimated $469K and leaving 32,739 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1491.

Focus Partners Wealth first reported a position in CORT in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.8M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Focus Partners Wealth held 32,739 shares of Corcept Therapeutics worth $1.32M as of Q1 2026.
  • Focus Partners Wealth sold 12,539 Corcept Therapeutics shares in Q1 2026, an estimated $469K.
  • Corcept Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #1491 holding.
  • Focus Partners Wealth first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Focus Partners Wealth's Corcept Therapeutics position peaked at $3.8M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.